Novartis announces new Gilenya® analyses to be presented at the 67th American Academy of Neurology Annual Meeting in Washington, DC, April 18-25, 2015

New analysis will confirm high efficacy of Gilenya® in achieving ‘no evidence of disease activity’ (NEDA4) in previously-treated highly-active RMS patients Separate analyses will show adding brain shrinkage to an existing assessment tool enhances ability to predict disability progression in … Read the full press release →